Literature DB >> 18341670

Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects.

Yoshiharu Suzuki, Masato Homma, Kosuke Doki, Fumio Itagaki, Yukinao Kohda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18341670      PMCID： PMC2485247          DOI： 10.1111/j.1365-2125.2008.03162.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.

Authors:  Ji H Choi; Yoon J Lee; Seong B Jang; Jong-Eun Lee; Kyung H Kim; Kyungsoo Park
Journal:  Br J Clin Pharmacol       Date:  2007-03-28       Impact factor: 4.335

2.  Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.

Authors:  Masahide Fukudo; Ikuko Yano; Satohiro Masuda; Maki Goto; Miwa Uesugi; Toshiya Katsura; Yasuhiro Ogura; Fumitaka Oike; Yasutsugu Takada; Hiroto Egawa; Shinji Uemoto; Ken-ichi Inui
Journal:  Clin Pharmacol Ther       Date:  2006-10       Impact factor: 6.875

3.  MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression.

Authors:  Wen Qian; Masato Homma; Fumio Itagaki; Hirokazu Tachikawa; Yoichi Kawanishi; Katsuyoshi Mizukami; Takashi Asada; Shinichi Inomata; Katsuya Honda; Nobuhiro Ohkohchi; Yukinao Kohda
Journal:  Biol Pharm Bull       Date:  2006-12       Impact factor: 2.233

4.  Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients.

Authors:  S Kawai; K Yamamoto
Journal:  Rheumatology (Oxford)       Date:  2005-11-01       Impact factor: 7.580

5.  Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.

Authors:  D Li; W Lu; J-Y Zhu; J Gao; Y-Q Lou; G-L Zhang
Journal:  J Clin Pharm Ther       Date:  2007-10       Impact factor: 2.512

6.  CYP3A5 variant allele frequencies in Dutch Caucasians.

Authors:  Ron H N van Schaik; Ilse P van der Heiden; John N van den Anker; Jan Lindemans
Journal:  Clin Chem       Date:  2002-10       Impact factor: 8.327

7.  Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene.

Authors:  Hiroshi Takane; Daisuke Kobayashi; Takeshi Hirota; Junzo Kigawa; Naoki Terakawa; Kenji Otsubo; Ichiro Ieiri
Journal:  J Pharmacol Exp Ther       Date:  2004-07-27       Impact factor: 4.030

8.  Pharmacokinetics of tacrolimus in liver transplant patients.

Authors:  W J Jusko; W Piekoszewski; G B Klintmalm; M S Shaefer; M F Hebert; A A Piergies; C C Lee; P Schechter; Q A Mekki
Journal:  Clin Pharmacol Ther       Date:  1995-03       Impact factor: 6.875
  8 in total
  7 in total

Review 1.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

2.  Dosing equation for tacrolimus using genetic variants and clinical factors.

Authors:  Chaitali Passey; Angela K Birnbaum; Richard C Brundage; William S Oetting; Ajay K Israni; Pamala A Jacobson
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

3.  A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients.

Authors:  Yan-xia Lu; Qing-hong Su; Ke-hua Wu; Yu-peng Ren; Liang Li; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

4.  Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study.

Authors:  Liang Li; Chuan-Jiang Li; Lei Zheng; Yan-Jun Zhang; Hai-Xia Jiang; Bo Si-Tu; Zhong-Hai Li
Journal:  Eur J Clin Pharmacol       Date:  2011-02-18       Impact factor: 2.953

5.  Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients.

Authors:  Yi Yi Htun; Nwe Nwe Than; Htar Kyi Swe
Journal:  Korean J Transplant       Date:  2020-03-31

6.  Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.

Authors:  Jing-Jing Zhang; Hua Zhang; Xiao-Liang Ding; Sheng Ma; Li-Yan Miao
Journal:  Eur J Clin Pharmacol       Date:  2012-10-25       Impact factor: 2.953

7.  Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis.

Authors:  Shinji Okabayashi; Taku Kobayashi; Eiko Saito; Takahiko Toyonaga; Ryo Ozaki; Shintaro Sagami; Masaru Nakano; Junichi Tanaka; Keiji Yagisawa; Satoshi Kuronuma; Osamu Takeuchi; Toshifumi Hibi
Journal:  Intest Res       Date:  2019-02-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.